Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ALDH1A1 | P00352 | 9/20 | 0.40 |
| ▸ | PKM | P14618 | 4/20 | 0.40 |
| ▸ | GAA | P10253 | 3/20 | 0.40 |
| ▸ | MEN1 | O00255 | 2/20 | 0.40 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.40 |
| ▸ | MAPT | P10636 | 1/20 | 0.40 |
| ▸ | ALOX15 | P16050 | 1/20 | 0.40 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.40 |
| ▸ | BRCA1 | P38398 | 1/20 | 0.40 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.40 |
| ▸ | CA2 | P00918 | 1/20 | 0.37 |
| ▸ | LMNA | P02545 | 1/20 | 0.37 |
| ▸ | THRB | P10828 | 1/20 | 0.37 |
| ▸ | CHRM5 | P08912 | 1/20 | 0.36 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4048676 | 0.82 | PHGDH (0.48) | ALDH1A1PKMMEN1KMT2AMAPT | |
| SCHEMBL4050465 | 0.80 | KMT2A (0.39) | ALDH1A1PKMGAAMEN1KMT2A | |
| SCHEMBL4050004 | 0.80 | RORC (0.48) | ALDH1A1MEN1KMT2AMAPTALOX15 | |
| SCHEMBL4050954 | 0.78 | LTA4H (0.46) | ALDH1A1PKMMEN1KMT2AMAPT | |
| SCHEMBL4051285 | 0.77 | FBP1 (0.39) | ALDH1A1PKMGAAKMT2AMAPT | |
| SCHEMBL93796 | 0.74 | CA2 (0.61) | ALDH1A1GAAMEN1KMT2AMAPT | |
| SCHEMBL1563242 | 0.74 | CA2 (0.61) | ALDH1A1GAAMEN1KMT2AMAPT | |
| SCHEMBL4050605 | 0.73 | ALDH1A1 (0.49) | ALDH1A1PKMGAAMAPTMAPK1 | |
| SCHEMBL1589664 | 0.73 | CA2 (0.59) | ALDH1A1GAAMEN1KMT2AMAPT | |
| Ammonia Solution, Strong SCHEMBL28149524 | 0.73 | CA2 (0.59) | ALDH1A1GAAMEN1KMT2AMAPT |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20090247579-A1 | 2-[3H-THIAZOL-2-YLIDINEMETHYL]PYRIDINES AND RELATED COMPOUNDS AND THEIR USE | CANCER RESEARCH TECHNOLOGY LIMITED | 2009-10-01 | — | — | US | disclosed |
| EP-2029584-A2 | 2-[3H-THIAZOL-2-YLIDINEMETHYL]PYRIDINES AND RELATED COMPOUNDS AND THEIR USE | Cancer Research Technology Limited (GB) | 2009-03-04 | — | — | EP | disclosed |
| WO-2007096618-A2 | 2-[3H-THIAZOL-2-YLIDINEMETHYL]PYRIDINES AND RELATED COMPOUNDS AND THEIR USE | CANCER RESEARCH TECHNOLOGY LIMITED (GB) | 2007-08-30 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090247579-A1 | 2-[3H-THIAZOL-2-YLIDINEMETHYL]PYRIDINES AND RELATED COMPOUNDS AND THEIR USE | RB1, RBBP5, RRM2B | ALDH1A1 1277/4885PKM 1368/4885GAA 3696/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.